ABRINDO A CAIXA DE PANDORA DOS NANOMEDICAMENTOS: HÁ REALMENTE MUITO MAIS ‘ESPAÇO LÁ EMBAIXO’

Detalhes bibliográficos
Autor(a) principal: Apolinário,Alexsandra Conceição
Data de Publicação: 2020
Outros Autores: Salata,Giovanna Cassone, Bianco,Arthur F. R., Fukumori,Claudio, Lopes,Luciana Biagini
Tipo de documento: Artigo
Idioma: por
Título da fonte: Química Nova (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-40422020000200212
Resumo: Limitations of conventional treatment and dosage forms prompted the investigation of novel approaches that combine efficacy, selectivity and fewer adverse effects. These are the main promises of nanomedicine, generally defined as the application of nanotechnology to the biomedical field. Despite the considerable advances over the years and the large number of publications resulting from the growth of nanomedicine, there are still many hurdles and unknown factors limiting its successful translation from promise to reality. These factors range from the lack of standardization in the terminology and regulations, to the lack of understanding of interactions between nanocarriers and the biological system, and their influence on drug pharmacodynamics. In this manuscript, we aim at presenting and discussing concepts and terminologies used in the nanomedicine field and examining the main types of nanocarriers and their effects to modulate biological barriers and aid drug transport, bioavailability and targeting.
id SBQ-3_60d3710b2d6669c373ea157a897f5849
oai_identifier_str oai:scielo:S0100-40422020000200212
network_acronym_str SBQ-3
network_name_str Química Nova (Online)
repository_id_str
spelling ABRINDO A CAIXA DE PANDORA DOS NANOMEDICAMENTOS: HÁ REALMENTE MUITO MAIS ‘ESPAÇO LÁ EMBAIXO’nanocarriersnanomedicinebiological barriersnanopharmacologyLimitations of conventional treatment and dosage forms prompted the investigation of novel approaches that combine efficacy, selectivity and fewer adverse effects. These are the main promises of nanomedicine, generally defined as the application of nanotechnology to the biomedical field. Despite the considerable advances over the years and the large number of publications resulting from the growth of nanomedicine, there are still many hurdles and unknown factors limiting its successful translation from promise to reality. These factors range from the lack of standardization in the terminology and regulations, to the lack of understanding of interactions between nanocarriers and the biological system, and their influence on drug pharmacodynamics. In this manuscript, we aim at presenting and discussing concepts and terminologies used in the nanomedicine field and examining the main types of nanocarriers and their effects to modulate biological barriers and aid drug transport, bioavailability and targeting.Sociedade Brasileira de Química2020-02-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-40422020000200212Química Nova v.43 n.2 2020reponame:Química Nova (Online)instname:Sociedade Brasileira de Química (SBQ)instacron:SBQ10.21577/0100-4042.20170481info:eu-repo/semantics/openAccessApolinário,Alexsandra ConceiçãoSalata,Giovanna CassoneBianco,Arthur F. R.Fukumori,ClaudioLopes,Luciana Biaginipor2020-05-12T00:00:00Zoai:scielo:S0100-40422020000200212Revistahttps://www.scielo.br/j/qn/ONGhttps://old.scielo.br/oai/scielo-oai.phpquimicanova@sbq.org.br1678-70640100-4042opendoar:2020-05-12T00:00Química Nova (Online) - Sociedade Brasileira de Química (SBQ)false
dc.title.none.fl_str_mv ABRINDO A CAIXA DE PANDORA DOS NANOMEDICAMENTOS: HÁ REALMENTE MUITO MAIS ‘ESPAÇO LÁ EMBAIXO’
title ABRINDO A CAIXA DE PANDORA DOS NANOMEDICAMENTOS: HÁ REALMENTE MUITO MAIS ‘ESPAÇO LÁ EMBAIXO’
spellingShingle ABRINDO A CAIXA DE PANDORA DOS NANOMEDICAMENTOS: HÁ REALMENTE MUITO MAIS ‘ESPAÇO LÁ EMBAIXO’
Apolinário,Alexsandra Conceição
nanocarriers
nanomedicine
biological barriers
nanopharmacology
title_short ABRINDO A CAIXA DE PANDORA DOS NANOMEDICAMENTOS: HÁ REALMENTE MUITO MAIS ‘ESPAÇO LÁ EMBAIXO’
title_full ABRINDO A CAIXA DE PANDORA DOS NANOMEDICAMENTOS: HÁ REALMENTE MUITO MAIS ‘ESPAÇO LÁ EMBAIXO’
title_fullStr ABRINDO A CAIXA DE PANDORA DOS NANOMEDICAMENTOS: HÁ REALMENTE MUITO MAIS ‘ESPAÇO LÁ EMBAIXO’
title_full_unstemmed ABRINDO A CAIXA DE PANDORA DOS NANOMEDICAMENTOS: HÁ REALMENTE MUITO MAIS ‘ESPAÇO LÁ EMBAIXO’
title_sort ABRINDO A CAIXA DE PANDORA DOS NANOMEDICAMENTOS: HÁ REALMENTE MUITO MAIS ‘ESPAÇO LÁ EMBAIXO’
author Apolinário,Alexsandra Conceição
author_facet Apolinário,Alexsandra Conceição
Salata,Giovanna Cassone
Bianco,Arthur F. R.
Fukumori,Claudio
Lopes,Luciana Biagini
author_role author
author2 Salata,Giovanna Cassone
Bianco,Arthur F. R.
Fukumori,Claudio
Lopes,Luciana Biagini
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Apolinário,Alexsandra Conceição
Salata,Giovanna Cassone
Bianco,Arthur F. R.
Fukumori,Claudio
Lopes,Luciana Biagini
dc.subject.por.fl_str_mv nanocarriers
nanomedicine
biological barriers
nanopharmacology
topic nanocarriers
nanomedicine
biological barriers
nanopharmacology
description Limitations of conventional treatment and dosage forms prompted the investigation of novel approaches that combine efficacy, selectivity and fewer adverse effects. These are the main promises of nanomedicine, generally defined as the application of nanotechnology to the biomedical field. Despite the considerable advances over the years and the large number of publications resulting from the growth of nanomedicine, there are still many hurdles and unknown factors limiting its successful translation from promise to reality. These factors range from the lack of standardization in the terminology and regulations, to the lack of understanding of interactions between nanocarriers and the biological system, and their influence on drug pharmacodynamics. In this manuscript, we aim at presenting and discussing concepts and terminologies used in the nanomedicine field and examining the main types of nanocarriers and their effects to modulate biological barriers and aid drug transport, bioavailability and targeting.
publishDate 2020
dc.date.none.fl_str_mv 2020-02-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-40422020000200212
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-40422020000200212
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv 10.21577/0100-4042.20170481
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Química
publisher.none.fl_str_mv Sociedade Brasileira de Química
dc.source.none.fl_str_mv Química Nova v.43 n.2 2020
reponame:Química Nova (Online)
instname:Sociedade Brasileira de Química (SBQ)
instacron:SBQ
instname_str Sociedade Brasileira de Química (SBQ)
instacron_str SBQ
institution SBQ
reponame_str Química Nova (Online)
collection Química Nova (Online)
repository.name.fl_str_mv Química Nova (Online) - Sociedade Brasileira de Química (SBQ)
repository.mail.fl_str_mv quimicanova@sbq.org.br
_version_ 1750318120128479232